NewsSudarshan Pharma Industries Board Meeting Scheduled on May 15, 2026 to Consider Foreign Currency Convertible Bonds IssuanceSudarshan Pharma Industries Board Meeting Scheduled on May 15, 2026 to Consider Foreign Currency Convertible Bonds Issuance
Sudarshan Pharma Industries Limited has intimated BSE Limited of a Board of Directors meeting scheduled for May 15, 2026, to consider and approve the issuance of Foreign Currency Convertible Bonds. The proposal is backed by shareholders' approval dated August 11, 2025, and an in-principle approval from BSE Limited dated September 26, 2025. The final issuance remains subject to applicable regulatory and statutory approvals. The intimation was filed on May 12, 2026, by Joint Managing Director Sachin Mehta, pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015.
*this image is generated using AI for illustrative purposes only.
Sudarshan Pharma Industries Limited has notified the stock exchange of an upcoming Board of Directors meeting, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled to be held on Friday, May 15, 2026, at the company's registered head office in Mumbai.
Board Meeting to Deliberate on FCCB Issuance
The primary agenda of the forthcoming board meeting is to consider and approve the proposal for the issuance of Foreign Currency Convertible Bonds (FCCBs), subject to receipt of applicable regulatory and statutory approvals. The intimation was filed by Joint Managing Director Sachin Mehta on May 12, 2026.
The key details of the board meeting intimation are summarised below:
| Parameter: | Details |
|---|---|
| Meeting Date: | Friday, May 15, 2026 |
| Filing Date: | May 12, 2026 |
| Regulatory Reference: | Regulation 29, SEBI (LODR) Regulations, 2015 |
| Agenda Item: | Consideration and approval of Foreign Currency Convertible Bonds issuance |
| Shareholders' Approval Date: | August 11, 2025 |
| BSE In-Principle Approval Date: | September 26, 2025 |
| Signatory: | Sachin Mehta, Joint Managing Director |
Background and Prior Approvals
The proposed FCCB issuance is backed by prior approvals at multiple levels. Shareholders of Sudarshan Pharma Industries had accorded their approval on August 11, 2025, for the proposed bond issuance. Subsequently, the company received an in-principle approval letter from BSE Limited on September 26, 2025, paving the way for the board to formally deliberate on the matter.
The company has clarified that the final approval for the issuance remains subject to receipt of all applicable regulatory and statutory approvals, as required under prevailing laws and exchange regulations.
Company Overview
Sudarshan Pharma Industries Limited is headquartered at 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai – 400092. The company's compliance correspondence can be directed to compliance@sudarshanpharma.com , and further information is available at www.sudarshanpharma.com .
Historical Stock Returns for Sudarshan Pharma Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.62% | +1.02% | -0.42% | +11.04% | +2.96% | +340.49% |
What is the target fundraising amount through the FCCB issuance, and which international markets or investor segments is Sudarshan Pharma Industries likely to tap for this offering?
How might the FCCB issuance impact Sudarshan Pharma's debt-to-equity ratio and overall capital structure, and what are the potential dilution risks for existing shareholders upon conversion?
What specific expansion plans, acquisitions, or R&D initiatives is Sudarshan Pharma Industries likely to fund with the proceeds from the Foreign Currency Convertible Bonds?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
